All analyses
5 min read

Last updated:

Magnesium bisglycinate: the effect of the form, and the effect of supplementation

Bisglycinate has established itself as the form you are supposed to take, and magnesium as the answer to stress, cramps and sleep. Trials say something else: the only well documented difference in form sets oxide apart from the rest, and on cramps a Cochrane review concludes there is no effect.

9 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Practitioner consulting her notes and micronutrition reference books
Practitioner consulting her notes and micronutrition reference books

A blood level says almost nothing about the store

The first question asked in consultation is almost always the same: how do I know if I lack magnesium. The answer disappoints. Serum magnesium represents only a tiny fraction of the body's magnesium, most of it sits in bone and cells. A normal level therefore does not rule out insufficient intake.

A systematic review published in 2011 reviewed twenty candidate markers from supplementation and depletion trials in healthy people. Only three respond to variations in intake: serum or plasma concentration, erythrocyte concentration, and urinary excretion. For all the others, the authors could not conclude, for lack of data.

That finding has a direct consequence. A blood panel remains used because it is available, not because it settles anything. A blood panel that comes back normal is not an argument to stop a correct dietary intake, and it is not one for supplementing either. Its reading belongs to the physician.

Form matters, but the dividing line is not the marketing one

The sales pitch for bisglycinate contrasts chelated forms, presented as absorbable, with cheap forms. The trial that compared these families directly tells a simpler story. Forty six healthy adults received 300 mg of elemental magnesium per day for sixty days, double blind against placebo, in three forms: amino acid chelate, citrate and oxide.

The two organic forms, citrate and amino acid chelate, were better absorbed than oxide at sixty days, measured by 24 hour urinary excretion. Citrate achieved the highest mean serum concentration. And oxide did not differ from placebo on any of the markers tracked.

The useful dividing line is therefore between oxide and the others, not between bisglycinate and citrate. Bisglycinate does belong to the amino acid chelate family tested in that trial, but no trial shows it does better than citrate on a clinical outcome. Paying three times more for that distinction is a matter of preference, not evidence.

On sleep, three trials and one hundred and fifty one people

This is the most widespread promise, and the thinnest body of evidence. A systematic review with meta-analysis published in 2021 found only three randomized trials comparing oral magnesium with placebo in older people with insomnia, in three countries, for a total of 151 participants.

The pooled result shows sleep onset shortened by 17.36 minutes compared with placebo, confidence interval 7.44 to 27.27 minutes. Total sleep duration gained 16 minutes, without reaching statistical significance. The authors rate all the trials at moderate to high risk of bias and the quality of evidence low to very low.

The authors' conclusion is honest and comes in two parts: the literature is insufficient to support a medical recommendation, and oral magnesium remains cheap and widely available. That is about all a practitioner can say without extrapolating.

On cramps, the answer is no

This is the most entrenched indication in habits, and the one where the data are clearest. A Cochrane review updated in 2020 covered eleven randomized trials and 735 participants, five trials in pregnant women and five in people with idiopathic cramps.

In older adults, mean age between 61.6 and 69.3 years, with idiopathic nocturnal cramps, the change in the number of cramps per week at four weeks is -9.59% compared with placebo, interval -23.14% to 3.97%, a non significant result, with near zero heterogeneity between trials. The proportion of people getting at least 25% fewer cramps does not differ either, relative risk 1.04, and that conclusion rests on a high certainty level.

Cramp intensity and duration do not move either. In other words, the result is not an absence of evidence but evidence of absence of a clinically useful effect, at least in this population. Trials conducted during pregnancy are too heterogeneous to pool and were judged at high risk of bias.

On blood pressure, a real and small effect

This is the best documented indication, and nobody talks about it. A meta-analysis published in 2016 in Hypertension pooled 34 double blind randomized placebo controlled trials, 2,028 participants, normotensive and hypertensive.

At a median dose of 368 mg per day for a median of three months, systolic pressure falls by 2.00 mmHg, interval 0.43 to 3.58, and diastolic by 1.78 mmHg, interval 0.73 to 2.82. The authors find that a dose of 300 mg per day or a duration of one month is enough to raise serum magnesium and lower pressure.

Two millimeters of mercury do not transform anyone's life in isolation. At population scale, and combined with the other levers that act on blood pressure, they are not nothing. That is the right register: a measured, modest effect that replaces no treatment.

What cohorts add, and the limit of their evidence

Observational studies are clearly more enthusiastic than trials. A 2016 dose-response meta-analysis gathered forty prospective cohorts and more than a million participants. Each additional 100 mg per day of dietary intake is associated with 22% less heart failure, 7% fewer strokes, 19% less type 2 diabetes and 10% lower all cause mortality. No association appears, however, with coronary heart disease or with cardiovascular disease taken as a whole.

A second meta-analysis, published in 2021 on nineteen publications and 1,168,756 participants, adds the distinction that matters. Dietary magnesium intake is associated with lower all cause mortality and lower cancer mortality. Intake from supplements, by contrast, is associated with nothing at all, neither total, cardiovascular nor cancer mortality.

That gap between food and capsule is the most instructive point in the file. A magnesium rich diet is made of legumes, whole grains, nuts and green vegetables, that is, foods that bring many other things at the same time. Attributing to the mineral what may belong to the whole plate is exactly the error these data help avoid.

Mood, the most fragile case in the file

A meta-analysis published in 2023 pooled seven randomized trials and 325 adult participants with a depressive disorder. It finds a marked decrease in depression scores on magnesium, standardized mean difference of -0.919, interval -1.443 to -0.396.

An effect of that size in 325 people in total should raise a flag rather than convince. Small trials regularly produce large effects that larger trials do not confirm, and the authors themselves call for larger work before any clinical transposition. A depressive disorder also belongs to the physician, and to no supplementation decided in coaching.

Where a practitioner stands, and the risk of too much

French data show the scale of both possible errors. In the NutriNet-Santé cohort, 76,925 adults reported their supplement use and three 24 hour dietary records. Among users, supplements reduce by 9% in men and 11% in women the prevalence of insufficient magnesium intake.

The same work notes that 5% of male users exceed the upper safety limit for magnesium. Supplementation therefore corrects a real insufficiency in some while pushing others past a threshold, which is what happens with intake decided without assessment. The most common adverse effect remains digestive, and it is more frequent with oxide.

The scope of a practitioner who is not a physician is clear. They can assess real dietary intake, work on sources, recall what trials show on sleep, cramps and blood pressure, and say what those trials do not show. Kidney failure, ongoing treatment or persistent symptoms require medical referral, and any reading of a level belongs to the physician. The reasoning holds for anti-aging supplements as a whole, of which magnesium is only one case.

Sources

  1. 1.Walker AF, et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res. 2003.
  2. 2.Witkowski M, et al. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res. 2011.
  3. 3.Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complement Med Ther. 2021.
  4. 4.Garrison SR, et al. Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev. 2020.
  5. 5.Zhang X, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016.
  6. 6.Fang X, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med. 2016.
  7. 7.Bagheri A, et al. Total, dietary, and supplemental magnesium intakes and risk of all-cause, cardiovascular, and cancer mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. Adv Nutr. 2021.
  8. 8.Moabedi M, et al. Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Front Psychiatry. 2023.
  9. 9.Fassier P, et al. Quantitative assessment of dietary supplement intake in 77,000 French adults: impact on nutritional intake inadequacy and excessive intake. Eur J Nutr. 2019.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.